Cargando…
Non-oral continuous drug delivery based therapies and sleep dysfunction in Parkinson’s disease
Continuous drug delivery (CDD) has emerged as a feasible and pragmatic therapeutic option for dopamine replacement therapy in advanced Parkinson’s disease (PD). CDD aims to mimic the physiological tonic dopamine release from striatal dopaminergic neurons and thus reduces the severity and duration of...
Autores principales: | Tall, P., Qamar, M. A., Batzu, L., Leta, V., Falup-Pecurariu, C., Ray Chaudhuri, K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645607/ https://www.ncbi.nlm.nih.gov/pubmed/37126118 http://dx.doi.org/10.1007/s00702-023-02640-7 |
Ejemplares similares
-
Viruses, parkinsonism and Parkinson’s disease: the past, present and future
por: Leta, Valentina, et al.
Publicado: (2022) -
Editorial: Movement Disorders and Sleep – Underlying Mechanisms, Clinical Aspects and Treatment
por: Falup-Pecurariu, Cristian, et al.
Publicado: (2019) -
Dry eye in Parkinson's disease: a narrative review
por: Ungureanu, Larisa, et al.
Publicado: (2023) -
Tolerability of non-ergot oral and transdermal dopamine agonists in younger and older Parkinson’s disease patients: an European multicentre survey
por: Rizos, A., et al.
Publicado: (2020) -
Motor and nonmotor complications in Parkinson’s disease: an argument for continuous drug delivery?
por: Chaudhuri, K. Ray, et al.
Publicado: (2013)